Know Cancer

forgot password

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Open (Enrolling)
Invasive Cancer, Sarcoma, Hematologic Cancer

Thank you

Trial Information

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Information about patients/participants' diseases and previous and future treatments and
outcomes will be recorded from medical records. A sample of tumor tissue that was already
collected and stored at MD Anderson or another institution will be collected. Blood (about 4
teaspoons) will be drawn so that researchers have a sample of normal cells to use for
comparison to cancer cells, a saliva sample or a cheek cell sample may be collected instead
of the blood sample.

The MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized
Cancer Therapy (IPCT) is committed to implementing personalized cancer therapy for all
patients coming to MD Anderson, transforming cancer patient management and improving
outcomes by making this approach the new standard of care. The ultimate goal is to perform
in-depth molecular characterization of all tumors, in order to tailor therapies offered and
identify best standard of care and clinical trial options.

Inclusion Criteria:

1. Patients must have histologically or cytologically documented invasive cancer,
suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign
tumors may also be consented at the discretion of the attending physician if
molecular profiling is felt to have potential clinical implications.

2. Patients must have the ability to understand and the willingness to sign a written
informed consent document.

3. Patients may be consented without confirming the amount and quality of archival
diagnostic or residual tissue available. However, research testing will only be
performed on patients who have sufficient archived diagnostic tissue or residual
tissue banked in one of the authorized tissue banks at MD Anderson available to
proceed with testing. The extent of testing may be modified based on amount of
tissue available. If a new biopsy is being ordered for clinical care or another
research study, or an operation is being performed testing can be ordered on that

Exclusion Criteria:


Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Database of Somatic Mutations and Clinical Characteristics

Outcome Description:

Collection and storage of tumor tissue specimens, blood and/or saliva samples of patients with cancer for somatic mutation analysis for assessing patients that may be eligible for new targeted therapy trials.

Outcome Time Frame:

20 years

Safety Issue:


Principal Investigator

Funda Meric-Bernstam, MD

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

March 2012

Completion Date:

Related Keywords:

  • Invasive Cancer
  • Sarcoma
  • Hematologic Cancer
  • Cancer
  • Molecular testing
  • Personalized Cancer Therapy Program
  • Bladder
  • Bone
  • Breast
  • Cytology
  • Endocrine
  • Gynecology
  • Endocrine - Neoplasia
  • genitourinary
  • Research Biorepository
  • Head and Neck
  • Aerodigestive Tract
  • Hematopathology
  • Human Cancer Genetics
  • Kidney
  • Leukemia
  • Lower Gastrointestinal
  • Lymphoma
  • Melanoma
  • Neurology
  • Brain
  • Non-Melanoma Skin
  • Pancreas
  • Pediatrics
  • Prostate
  • Breast Cancer Patients, Serum
  • Plasma
  • Soft Tissue Sarcoma
  • Thoracic
  • Lung
  • S.P.O.R.E.
  • Upper Gastrointestinal
  • Hematologic Neoplasms
  • Sarcoma



UT MDACC/Regional Cancer CentersHouston, Texas  77030